Q-omics provides the consensus-scored AMD1P3 profile across patient tissues and cancer cell-line models. AMD1P3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, AMD1P3 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, AMD1P3 RNA expression shows 18,249 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where AMD1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMD1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMD1P3 survival associations across molecular data types. AMD1P3 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMD1P3 RNA expression–survival associations across cancer types. High AMD1P3 expression shows unfavorable associations in ACC, LIHC, KICH and MESO, but favorable associations in SKCM and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for AMD1P3 RNA expression.
This table summarizes AMD1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for AMD1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMD1P3 shows lower tumor expression in LUSC and higher tumor expression in COAD, LIHC, READ, LUAD and LUSC. The COAD box plot shows higher AMD1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.255, t-test p < 0.001).
This table shows molecular features associated with AMD1P3 in patient tissues and cancer cell lines. In patient samples, AMD1P3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
